• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ASCO GU: Pfizer touts Talzenna's strong showing in PARP prostate cancer battle with...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 17, 2023 at 09:42: AM
via Pfizer may be the last major oncology player to put a wager on a PARP inhibitor in prostate cancer, but the New York pharma appears to have a winning regimen, partly thanks to its Astellas-partnered stalwart Xtandi.

article source
 

<



Similar threads

cafead
ASCO: Merck KGaA, Pfizer&#039;s Bavencio combo misses survival mark in crowded kidney...
Replies
0
Views
87
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO: Pfizer&#039;s Ibrance fails to extend lives in newly diagnosed breast cancer. Will...
Replies
0
Views
186
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO: Merck&#039;s Keytruda targets Pfizer&#039;s shaky Sutent post-surgery use in kidney...
Replies
0
Views
212
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO: Pfizer, Merck KGaA&#039;s Bavencio posts win in rare gynecological cancer
Replies
0
Views
194
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer
Replies
0
Views
148
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote